| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| MIF | macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator... |
|---|---|
| PIF | paratoid isoelectric focusing variant protein; peak inspiratory flow; proinsulin-free; prolactin-inh... |
| MRF | Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence... |
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| RIF | radiological interface; release-inhibiting factor; rifampin; right iliac fossa; rosette-inhibiting f... |
| MMMT | Malignant mixed Mullerian tumor |
|---|---|
| MMT | Mixed Mullerian Tumours |
| MD | Mullerian duct |
| PMDS | Persistent Mullerian Duct Syndrome |
| GIF | Glycosylation inhibiting factor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| mullerian inhibiting factor | A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin. Synonym: mullerian inhibiting factor. (05 Mar 2000) |
|---|
| mullerian inhibiting substance | A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin. Synonym: mullerian inhibiting factor. (05 Mar 2000) |
|---|---|
| mullerian regression factor | Mullerian duct inhibitory factor, a non-steroidal substance of foetal testicular origin that acts unilaterally to inhibit development of the paramesonephric (mullerian) ducts and acts with testosterone to promote development of the vas deferens and related structures. (05 Mar 2000) |
| prolactin-inhibiting factor | A substance of hypothalamic origin capable of inhibiting the synthesis and release of prolactin. Synonym: prolactin-inhibiting factor, prolactin-inhibiting hormone. Origin: prolactin + G. Stasis, standing still, + -in (05 Mar 2000) |
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| malignant mixed mullerian tumour | A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. Synonym: malignant mixed mullerian tumour. (05 Mar 2000) |
| persistent mullerian duct syndrome | <syndrome> Familial disorder with presence of fallopian tube, uterus, and testis in a male. Deficient mullerian inhibitory substance secondary to Sertoli cell defect. Synonym: hernia uteri inguinale. (05 Mar 2000) |
| mixed tumour, mullerian | A tumour, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of oestrogen has been postulated as a possible aetiological factor in this tumour. (holland et al., cancer medicine, 3d ed, p1703) (12 Dec 1998) |
| mullerian | <anatomy> Of, pertaining to, or discovered by, Johannes Muller. <anatomy> Mullerian ducts, the sustentacular or connective-tissue fibres which form the framework of the retina. Source: Websters Dictionary (01 Mar 1998) |
| mullerian adenosarcoma | <tumour> A tumour of the uterus or ovaries, of low grade malignancy, characterised by benign appearing glands and a sarcomatous stroma. (05 Mar 2000) |
| mullerian duct | <radiology> FEMALE, fallopian tubes, uterus, vagina Male, appendix testis, prostatic utricle anomalies: mullerian agenesis most likely to be absent uterus and vagina, incomplete fusion most likely to be bicornuate/double uterus, double vagina, both associated with renal agenesis Cf: wolffian duct (12 Dec 1998) |
| mullerian ducts | Two ducts of the embryo which empty into the cloaca, and which in the female develop into vagina, uterus and oviducts; in the male they disappear except for the vestigial vagina masculina and the appendix testis. (12 Dec 1998) |
| melanotropin release-inhibiting hormone | Inhibits synthesis and release of melanotropin. Synonym: melanotropin release-inhibiting hormone. Origin: melanotropin + G. States, stationary, + -in (05 Mar 2000) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| pituitary hormone release inhibiting hormones | Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. (12 Dec 1998) |
| msh release-inhibiting hormone | <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh). Chemical name: Melanostatin (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|